Qiagen (QGEN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 4.55%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.56 per share when it actually produced earnings of $0.55, delivering a surprise of -1.79%. Over the last four quarters, t ...

预测财报 - 预计Qiagen (QGEN)将在即将发布的财报中每股盈利为0.44美元，同比下降17%[1] - 预计收入将达到454.97亿美元，较去年同期下降6.3%[1] 分析师预期 - 在过去30天内，对本季度的共识每股收益预期没有进行修订，这表明分析师在此期间内对其最初预测进行了集体重新考虑[2] - 投资者通常依赖于共识盈利和收入预期来评估本季度的业绩，但深入分析分析师对某些关键指标的预测往往能提供更全面的理解[4] 财报前考虑 - 在公司发布财报之前，重要的是要考虑到对盈利预测所做的任何修订，这些修订是预测投资者对股票可能行为的关键标尺[3]

Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: C ...

Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - Click here: C ...

QIAGEN N.V. (QGEN) recently announced a sequence of new products to augment cancer research further and to enable urine collection and stabilization as a new approach for liquid biopsy. The three new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid- 2024. The new products are likely to be featured at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, California, from Apr 5-10. Product Details The first pr ...

Venlo, the Netherlands, April 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a series of new products to further enhance cancer research as well as to enable urine collection and stabilization as a new approach for liquid biopsy. These three new products, along with the IVD version of QIAGEN's digital PCR platform QIAcuity set for launch in mid-2024, are to be featured at the annual meeting of the American Association for Cancer Research (AACR) in San D ...

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers. This collaboration f ...

公司股价及市值 - QIAGEN在2023年的股价表现相对良好，纽约证券交易所的股价为43.43美元，法兰克福证券交易所的股价为39.40欧元[11] - QIAGEN在2023年年底的市值为9911万美元和8991万欧元[15] - QIAGEN在2023年的平均每日交易量约为1.02百万股[17] - QIAGEN在2023年的股东大会中，约有69%的股份代表出席，对所有议程都表示支持[16] - QIAGEN的全球股票在纽约证券交易所和法兰克福证券交易所交易，为投资者提供更多选择[14] 公司销售情况 - 2023年分子诊断销售额为10.355亿美元，较2022年和2021年分别下降了7.9%和9.3%[35] - 2023年生命科学销售额为9.298亿美元，较2022年和2021年分别下降了8.4%和16.1%[35] - 2023年总销售额为19.653亿美元，较2022年和2021年分别下降了8.2%和4.7%[36] - 预计总可寻址市场规模每年超过110亿美元[36] - 与500,000多客户合作，销售给分子诊断和生命科学两大客户群体[34] 公司全球业务及发展战略 - 公司在2023年的销售中，中国、巴西、印度、韩国、墨西哥和土耳其等六个增长市场贡献了12%的净销售额[45] - 公司的业务不受季节因素显著影响，历史上销售的大部分是面向研究人员、大学、政府实验室和私人基金会，这些机构的资金来源主要依赖于政府机构的拨款[46] - 公司致力于扩大在分子诊断和生命科学领域的全球领导地位，通过创新和研发资源来满足客户在医疗保健和研究实验室中的需求[47] - 公司计划继续扩大业务至中东和亚洲等其他快速增长市场[147] 公司财务状况及风险管理 - 公司在2023年的净销售额为1965.3百万美元，较2022年的2141.5百万美元和2021年的2251.7百万美元有所下降[43] - 公司在2023年的运营和财务审查中提到了最近的生产能力扩展项目的支出，以及对BLIRT S.A.和Verogen, Inc.的投资[63] - 公司的风险管理目标是识别可能严重威胁成功的风险，并及时实施缓解措施[105] - 公司的已识别风险分为基础业务风险、业务增长风险和基础业务风险三种类型[106] - 全球经济条件可能会对公司的业务、运营结果和财务状况产生重大影响[115] 公司可持续发展及社会责任 - 作为一家领先的 Sample to Insight 解决方案提供商，QIAGEN 在支持全球客户的同时，致力于通过产品的使用推动科学进步，改善全球患者的预后[196] - 在 2023 年，QIAGEN 的增长策略仍然以五大支柱为基础，致力于提供最佳产品和服务组合，同时尽可能减少对地球的影响[196] - 公司的可持续性战略由 Corporate ESG 委员会制定和批准，该委员会由公司各部门代表组成，负责推动可持续性战略的实施[198]

It has been about a month since the last earnings report for Qiagen (QGEN) . Shares have added about 1.1% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Qiagen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. QIAGEN Q4 Earnings Lag, Operating Margin Expands QIA ...

QIAGEN N.V. (QGEN) recently launched QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries. This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery. The latest development will strongly boost the QIAGEN Digital Insights (“QDI”) bioinformatics business of the Genomics / NGS product group. News in Detail QIAGEN Biomed ...